Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Ashley Cupstid

Physician Assistant Irving, TX Physician Assistant

NPI 1760109896 CMS profile 11435160

6750 N MacArthur Blvd Ste 260, Irving, TX 75039

Open in the dashboard

General payments

$12,613

497 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Cupstid of Irving, TX is reported in the CMS Open Payments database as having received $12,613 across 497 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,378 228
2024 General $3,012 133
2023 General $4,224 136

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Cupstid
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Ashley Cupstid were reported at $5,378. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Ashley Cupstid Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $4,224 $167 $52–$557 $160
2024 $3,012 $178 $55–$600 $164
2025 $5,378 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $2,008 90 payments
  2. Genzyme Corporation $1,451 40 payments
  3. Regeneron Healthcare Solutions, Inc. $1,243 36 payments
  4. Janssen Biotech, Inc. $989 29 payments
  5. Galderma Laboratories, L.P. $810 39 payments
  6. Incyte Corporation $703 23 payments
  7. Dermavant Sciences, Inc. $680 23 payments
  8. Amgen Inc. $620 27 payments
  9. Lilly USA, LLC $574 24 payments
  10. Arcutis Biotherapeutics, Inc. $478 29 payments
  11. Other $3,058 137 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $11,876 488 payments
  2. Education $737 9 payments
Products named General payments · program years 2023–2025
  1. DUPIXENT Immunology $1,911 46 payments
  2. TREMFYA $989 29 payments
  3. SKYRIZI Immunology $983 47 payments
  4. VTAMA $892 28 payments
  5. DUPIXENT Immunology And Inflammation $749 16 payments
  6. NEMLUVIO $733 34 payments
  7. OPZELURA $620 22 payments
  8. SKYRIZI Immunology $514 31 payments
  9. Otezla $476 26 payments
  10. TALTZ $448 22 payments
  11. Other $4,660 213 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

542

Median for Physician Assistant: 241

Drug cost

$165,442

Median for Physician Assistant: $4,110

Branded share of claims

7.9%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 43 $156,554
Clobetasol Propionate Generic 60 $2,620
Triamcinolone Acetonide Generic 121 $1,810
Doxycycline Hyclate Generic 28 $1,017
Ketoconazole Generic 60 $950
Mupirocin Generic 56 $495
Mometasone Furoate Generic 19 $491
Minocycline Hcl Generic 13 $429
Hydrocortisone Generic 56 $332
Clindamycin Phosphate Generic 15 $284

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$53,270

Of which drugs: $71

Medicare patients

327

Average age 75

Services billed

1,501

181 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 49%
Ischemic heart disease 24%
Depression 20%
Chronic kidney disease 19%
Cancer 19%
Diabetes 18%
Atrial fibrillation 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 20 100 $71

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $390
  • Regeneron Healthcare Solutions, Inc. $130
$520 43 —
VTAMA
  • Dermavant Sciences, Inc. $501
$501 — —
SKYRIZI
  • AbbVie, Inc. $418
$418 — —
TREMFYA
  • Janssen Biotech, Inc. $253
$253 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $218
$218 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

497 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record